The Pharma Data

DECEMBER 23, 2020

In July, ViiV Healthcare, which is based in London, resubmitted the New Drug Application (NDA) for once-monthly dosing of cabotegravir and rilpivirine to the U.S. Food and Drug Administration (FDA), and further regulatory applications have been submitted and are being reviewed by other regulatory bodies worldwide, the company said.

Drugs 52

Drugs Licensing Licensing Vaccination 52

Drug Discovery World

JANUARY 19, 2023

pDNA is a critical raw material for advanced therapeutics including mRNA and viral vector-based cell and gene therapies and vaccines. Plasmid DNA: a critical reagent pDNA is the starting material for the development of many cell and gene therapy products, irrespective of the mode of action. billion by 2030 (BioSpace, 11 August 2022).

DNA 52

DNA Manufacturing Gene Therapy Gene 52

The Pharma Data

OCTOBER 19, 2020

DB ( Becton, Dickinson and Company ) received a CE mark for its BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes for assessing immune function in COVID-19 patients. Testing Therapies, Antivirals and Vaccines. There has been some discussion of running challenge trials for COVID-19 vaccines. Please read more here. .

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

XTalks

AUGUST 18, 2020

SalivaDirect, a saliva-based COVID-19 test that was tested among players of the National Basketball Association (NBA), has been given emergency use authorization (EUA) by the US Food and Drug Administration (FDA). The EUA comes after Yale partnered with the NBA to study the efficacy of the saliva-based test.

FDA Approval 90

FDA Approval Reagent RNA Genome 90

Drug Discovery World

NOVEMBER 30, 2023

coli expression systems and is using high-throughput expression pipelines to screen constructs for optimal expression to generate protein and cellular reagents. GSK has developed high-throughput mammalian and E. From a product perspective, RedShiftBio had the Aurora protein analyser with them in Lisbon this year.

Antibody 59

Antibody Protein Engineer In-Vivo 59

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 91

Gene Editing Gene DNA Engineer 91

Drug Discovery World

FEBRUARY 15, 2023

Evolution of such defence mechanisms can lead to multi-drug resistance, further disease progression, and cancer metastasis. Benefits over 2D monolayer culture include the possibility of investigating drug penetration and drug resistance offered by the tumour cells.

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

OCTOBER 12, 2022

Furthermore, the sensitivity of the fluorescent label was shown to be around x100 greater than 2-aminobenzamide, a reagent that has been used extensively in the past to label glycans. . An understanding of these structures is important in their role as antigens and as candidate targets for vaccines. . Drug Discov. Jefferis, R.

Protein 52

Protein Gene Therapy Antibody Production 52

Drug Discovery World

FEBRUARY 8, 2023

This approach, however, can be time-consuming, laborious, and require expensive reagents, including serotype-specific antibodies. Cheeseman is interested in pushing the boundaries of biomolecular analysis to eventually enable real-time release of biomolecular drugs.

Gene Therapy 52

Gene Therapy Gene Antibody Production 52